aRigen Pharmaceuticals Inc.

Shares of Insmed tumbled as low as 36.8%, or $1.60, on 10 October after the Monmouth Junction, New Jersey-based firm revealed the US FDA plans to continue the clinical hold placed on the company's Pha

In Vitro Diagnostics Mergers & Acquisitions

Green Cross Corp has acquired rights in South Korea to aRigen Pharmaceuticals' lotilibcin (WAP-8294A2), in what is the first licensing deal for the novel anti-MRSA agent. The agreement gives Green Cro

In Vitro Diagnostics Acquisitions /In Vitro Diagnostics Abbott Laboratories Inc. Celera Corp. In a four-year deal, Celera Corp. has licensed Abbott Laboratories Inc. exclusive rights to distri